



Indrayani Biotech Limited

1133/5 F C Road, Opp. Police Grounds
Pune 411 016

Tel/Fax: +91 20 25662021

Email: info@indrayani.com

www.indrayani.com

CIN: L24231PNI992PLC065801

November 14, 2018

To,
Bombay Stock Exchange Ltd.
Department of Corporate Services,
25st Floor, P.J. Towars, Dalal Street,
Mumbai - 400 001.

Dear Sir,

Ref.: Scrip code '526445'

Re.: Unaudited Financial Results for the quarter and six months ended September 30, 2018.

The Board of Directors, in their meeting duly held on 14th November, 2018 has approved the Unaudited Financial Results for the quarter and six months ended on September 30, 2018.

Pursuant to Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015, we enclose the followings:

- 1) Statement of the Unaudited Financial Results for the Quarter ended and Six months ended 30th September, 2018.
- 2) The Limited Review Report on the Financial Statement for the Quarter ended and Six months ended 30th September, 2018.

Please take on your records.

Thanking you,

Yours faithfully,
For **Indrayani Biotech Ltd.**



Sayee Sundar Kasiraman
Managing Director
DIN: 01295584

INDRAYANI BIOTECH LIMITED

Regd. Office: 1133/5, F. C. Road, Opp. Police Grounds, Pune - 411 016.

Telefax: 020 - 25662021, Web: www.indrayani.com, Email: info@indrayani.com, CIN: L24231PN1992PLC065801

**STATEMENT OF STANDALONE UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND HALF YEAR ENDED
30TH SEPTEMBER, 2018**

		Rs. In Lakhs					
PARTICULARS	Quarter Ended			Half Year Ended		Year Ended	
	30 th September, 2018	30 th June, 2018	30 th September, 2017	30 th September, 2018	30 th September, 2017	31 st March, 2018	
	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited	
Income							
I Revenue from Operations	-	-	-	-	-	-	
II Other Income	-	-	-	-	-	-	
III Total Income	-	-	-	-	-	-	
IV Expenses							
Cost of Materials consumed	-	-	-	-	-	-	
Purchase of stock-in-trade	-	-	-	-	-	-	
Changes in inventories of finished goods, work-in-progress and stock-in-trade	-	-	-	-	-	-	
Employee benefits expenses	0.90	0.60	0.90	1.50	1.50	3.60	
Finance Cost	-	0.01	-	0.01	0.02	0.02	
Depreciation and amortisation expense	-	-	-	-	-	-	
Other expenses							
1. Advertisements	0.54	0.23	0.15	0.77	0.34	0.71	
2. Audit Fees	-	-	-	-	-	0.71	
3. Legal & Professional Expenses	3.48	0.38	0.94	3.86	4.43	6.89	
4. Rates & Taxes	-	0.03	-	0.03	0.31	0.03	
5. Telephone & Postage	-	-	-	-	-	0.01	
6. Travelling & Conveyance	-	-	-	-	-	0.05	
7. Filing Fees & Subscription	0.12	0.21	0.22	0.34	-	0.39	
8. Printing & Stationery	-	-	-	-	-	-	
9. Prior Period Expenses	-	-	-	-	-	-	
10. Business Promotion	0.02	-	-	0.02	-	-	
Total Other Expenses	4.17	0.85	1.31	5.02	5.08	8.78	
Total Expenses (IV)	5.07	1.46	2.21	6.53	6.60	12.40	
V Profit / (Loss) before exceptional and tax (I-IV)	(5.07)	(1.46)	(2.21)	(6.53)	(6.60)	(12.40)	
VI Exceptional Items	-	-	-	-	-	-	
VII Profit / (Loss) before tax (V-VI)	(5.07)	(1.46)	(2.21)	(6.53)	(6.60)	(12.40)	
VIII Tax expense							
Current Tax	-	-	-	-	-	-	
Deferred Tax	-	-	-	-	-	-	
IX Net Profit / (Loss) for the period from continuing operations (VII-VIII)	(5.07)	(1.46)	(2.21)	(6.53)	(6.60)	(12.40)	
X Profit / (Loss) from discontinued operations	-	-	-	-	-	-	
XI Tax expense of discontinued operations	-	-	-	-	-	-	
XII Net Profit / (Loss) from Discontinued operations after tax (X-XI)	-	-	-	-	-	-	
XIII Profit / (Loss) for the period (IX+XII)	(5.07)	(1.46)	(2.21)	(6.53)	(6.60)	(12.40)	

XIV	Other Comprehensive Income (OCI)						
	A (i) Items that will not be reclassified to profit or loss	-	-	-			
	(ii) Income tax relating to items that will not be reclassified to profit or loss	-	-	-			
	B (i) Items that will be reclassified to profit or loss	-	-	-			
	(ii) Income tax relating to items that will be reclassified to profit or loss	-	-	-			
XV	Total Comprehensive Income for the period (XIII+XIV) (Comprising Profit (Loss) and Other Comprehensive Income for the period).	(5.07)	(1.46)	(2.21)	(6.53)	(6.60)	(12.40)
XVI	Earnings per share (for continuing operation) :						
	Basic:	(0.14)	(0.04)	(0.06)	(0.17)	(0.18)	(0.34)
	Diluted:	(0.14)	(0.04)	(0.06)	(0.17)	(0.18)	(0.34)
XVII	Earnings per share (for discontinued operation) :						
	Basic:	-	-	-	-	-	-
	Diluted:	-	-	-	-	-	-
XVIII	Earnings per share (for discontinued & continuing operation)						
	Basic:	(0.14)	(0.04)	(0.06)	(0.17)	(0.18)	(0.34)
	Diluted:	(0.14)	(0.04)	(0.06)	(0.17)	(0.18)	(0.34)

Notes:

1. The above financial results have been reviewed by the Audit Committee and approved by the Board of Directors in the meeting held on 14th November, 2018. The above financial results are subject to "Limited Review" by the Statutory Auditors of the Company.
2. This statement has been prepared in accordance with the Companies (Indian Accounting Standards) Rules, 2015 (Ind AS), prescribed under Section 133 of the Companies Act, 2013, and other recognised accounting practices and policies to the extent applicable.
3. The format for unaudited quarterly results as prescribed in SEBI's Circular CIR/CFD/CMD/15/2015 dated 30th November 2015 has been modified to comply with the requirements of SEBI's circular dated 05th July 2016, Ind AS and Schedule III (Division II) to the Companies Act, 2013, which are applicable to companies that are required to comply with Ind AS.
4. The Company operates in a single business segment. Hence, results for only one segment are given.

For **Indrayani Biotech Limited**

S. Sundar Kasiraman



Sayee Sundar Kasiraman
Managing Director
DIN: 01295584

Date: 14th November, 2018
Place: Pune

STANDALONE STATEMENT OF ASSETS AND LIABILITIES AS AT 30TH SEPTEMBER, 2018.

(Rs. in Lakhs)

Sr. No.	Standalone Statement of Assets and Liabilities Particulars	As At 30/09/2018	As At 30/09/2017	As At 31/03/2018
		Unaudited	Unaudited	Audited
A.	ASSETS			
1.	Non-current assets			
a)	Property, plant and equipment	-	-	-
b)	Capital work in progress	-	-	-
c)	Investment property	-	-	-
d)	Goodwill	-	-	-
e)	Other intangible assets	-	-	-
f)	Intangible assets under development	-	-	-
g)	Biological assets other than bearer plants	-	-	-
h)	Financial assets	-	-	-
	i) Investments	-	-	-
	ii) Trade receivables	-	-	-
	iii) Loans	-	-	-
	iv) Other non-current financial assets	-	-	-
i)	Deferred tax assets (net)	-	-	-
j)	Others non-current assets	-	-	-
	Sub Total Non - Current Assets	-	-	-
2.	Current Assets			
a)	Inventories	-	-	-
b)	Financial Assets			
	i) Investments	-	-	-
	ii) Trade Receivables	-	-	-
	iii) Cash & Cash Equivalents	0.02	-	0.01
	iv) Bank Balances other than (iii) above	0.10	0.84	1.04
	v) Loans	-	-	-
	vi) Other financial assets	-	-	-
c)	Current tax assets (net)	-	-	-
d)	Other current assets	-	-	-
	Sub Total - Current Assets	0.12	0.84	1.05
	Total Assets	0.12	0.84	1.05
B.	EQUITY AND LIABILITIES			
	EQUITY			
a)	Equity share capital	364.39	364.39	364.39
b)	Other equity			
	Reserves	(431.04)	(418.71)	(424.52)
	LIABILITIES			
1.	Non-current liabilities			
a)	Financial liabilities			
	i) Borrowings	66.75	55.00	60.00
	ii) Trade payables	-	-	-
	iii) Other financial liabilities	-	-	-
b)	Provisions	-	-	-
c)	Deferred tax liabilities (net)	-	-	-
d)	Other non-current liabilities	-	-	-
	Sub Total Non - Current Liabilities	66.75	55.00	60.00

2. Current liabilities			
a) Financial liabilities	-	-	-
i) Borrowings	-	-	-
ii) Trade payables	-	0.07	0.44
iii) Other financial liabilities	-	0.09	-
b) Other current liabilities	0.03	-	0.74
c) Provisions	-	-	-
d) Current tax liabilities (Net)	-	-	-
Sub Total - Current Liabilities	0.03	0.16	1.18
Total Equity and Liabilities	0.12	0.84	1.05

For **Indrayani Biotech Limited**

K. Jayan Sundar



Sayee Sundar Kasiraman
 Managing Director
 DIN: 01295584

Date: 14th November, 2018
 Place: Pune



Limited Review Report on Quarterly Standalone Financial Results of INDRAYANI BIOTECH LIMITED pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

To the Board of Directors,

INDRAYANI BIOTECH LIMITED

We have reviewed the accompanying statement of unaudited standalone financial results of **INDRAYANI BIOTECH LIMITED** ('the Company') for the quarter ended September, 30th, 2018 ('the Statement'), being submitted by the Company pursuant to the requirements of Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 as modified by Circular No. CIR/CFD/FAC/62/2016 dated July 5, 2016 (Listing Regulations).

This statement, which is the responsibility of the Company's Management and has been approved by the Board of Directors in their meeting held on 14th November, 2018. Our responsibility is to issue a report on the Statement based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity', issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial results are free of material misstatements. A review is limited primarily to inquiries of Company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, Nothing has come to our attention that causes us to believe that the accompanying statement of unaudited standalone financial results prepared in accordance with applicable Indian Accounting Standards (IND AS) prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and SEBI Circular dated 5 July 2016 including the manner in which it is to be disclosed, or that it contains any material misstatement.

for Venkatesh and Co,
Chartered Accountants
Fr.No 004636S

CA Dasaraty V
M.No 026336
Partner



Place: Chennai
Date: 14/11/2018